AxoGen (NASDAQ:AXGN) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of AxoGen (NASDAQ:AXGN) from a hold rating to a buy rating in a research note published on Tuesday.

Several other analysts have also weighed in on AXGN. JMP Securities increased their price target on AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a report on Friday, August 9th. Raymond James assumed coverage on shares of AxoGen in a report on Monday, July 1st. They issued an “outperform” rating and a $13.00 price target on the stock. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of AxoGen in a research note on Thursday, June 20th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

AxoGen Price Performance

NASDAQ:AXGN opened at $13.16 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.32 and a current ratio of 3.51. AxoGen has a 52-week low of $3.45 and a 52-week high of $15.23. The firm has a market capitalization of $575.16 million, a price-to-earnings ratio of -26.32 and a beta of 1.13. The stock has a fifty day moving average of $13.31 and a 200 day moving average of $9.44.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. The business had revenue of $47.91 million during the quarter, compared to analyst estimates of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. On average, research analysts expect that AxoGen will post -0.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in shares of AxoGen during the 3rd quarter worth $56,000. Koss Olinger Consulting LLC acquired a new position in shares of AxoGen in the 2nd quarter valued at approximately $75,000. Lazard Asset Management LLC raised its stake in shares of AxoGen by 30.1% in the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of AxoGen in the 2nd quarter valued at approximately $125,000. Finally, BNP Paribas Financial Markets lifted its stake in AxoGen by 8.6% during the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock worth $168,000 after purchasing an additional 1,651 shares during the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.